Posted by Michael Wonder on 01 Dec 2018
FDA accepts filing of new oestrogen-free oral contraceptive developed by Exeltis
29 November 2018 - This new method of contraception could offer an improved bleeding profile and greater flexibility for female population.
The pharmaceutical multinational Exeltis has received acceptance from the US FDA of the filing of Slinda (4mg drospirenone only pill), the novel oral contraceptive developed by the company. The Prescription Drug User Fee Act date is expected during the 27 May 2019.
Slinda is an investigational oestrogen-free oral contraceptive, with a 24/4 dose regimen that is believed to have a favourable safety and efficacy profile.
